On May 12, 2022, Aadi Bioscience, Inc. ("Aadi") announced positive first-quarter financial results for its first-quarter clinical trial.  According to the company's press release announcing the launch of the clinical trial, Aadi Bioscience's product, FYARRO, was the first and only FDA-approved drug specifically indicated for advanced malignant PEComa.  According to the company's press release, FYARRO has been well received by patients and their treating physicians alike.  In the first quarter of this year, the company reported positive first-quarter sales of FYARRO.  In the second quarter, the company reported positive first-quarter net sales of FYARRO.  In the third quarter, the company reported positive first-half net sales of FYARRO.  The company also reported positive first-half net sales.  The company's stock price increased more than 20% in the first half of the year.  The company's stock price increased by more than 30%.  The company's stock price increased more than 40% in the second half of the year.  The company's cash position remained strong at approximately $130 million.  The company's revenue increased by 28% in the first quarter.  The company's stock price increased by another 20% in the second quarter.  The company's stock price increased 23% in the third quarter.  The company's CEO, Brendan Delaney, and COO, Loretta Itri, announced the launch of FYARRO on March 31, 2022.  The company's stock price increased by 23% in the second quarter.  The company also announced that it has signed an agreement to pay a $80 million settlement with the SEC.  The settlement is subject to court approval.  The SEC's continuing investigation is being conducted by Jiale Song and Brendan Delaney, and the litigation will be led by Mr. Delaney.  The SEC appreciates the assistance of the U.S. Attorney's Office for the District of New Jersey, the Federal Bureau of Investigation, and the U.S. Department of Health and Human Services.